-
公开(公告)号:US20060240526A1
公开(公告)日:2006-10-26
申请号:US11424030
申请日:2006-06-14
申请人: Jesper Haaning , Kim Andersen , Claus Bornaes
发明人: Jesper Haaning , Kim Andersen , Claus Bornaes
IPC分类号: C07K14/745 , C07H21/04 , C12P21/04
CPC分类号: C12N9/6437 , A61K38/4846 , C12N9/647 , C12Y304/21021
摘要: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
-
公开(公告)号:US20050164932A1
公开(公告)日:2005-07-28
申请号:US11021239
申请日:2004-12-22
申请人: Jesper Haaning , Kim Andersen , Claus Bornaes
发明人: Jesper Haaning , Kim Andersen , Claus Bornaes
CPC分类号: C12N9/6437 , A61K38/4846 , C12N9/647 , C12Y304/21021
摘要: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
摘要翻译: 人因子VII或人因子VIIa的Gla结构域变体,其相对于人因子VII或人因子VIIa包含1-15个氨基酸修饰,其中通过在位置34取代引入疏水性氨基酸残基; 或在36位具有氨基酸取代; 并使用变体治疗脑内出血(ICH)或创伤。
-
公开(公告)号:US20070117756A1
公开(公告)日:2007-05-24
申请号:US11643535
申请日:2006-12-21
申请人: Jesper Haaning , Kim Andersen , Claus Bornaes
发明人: Jesper Haaning , Kim Andersen , Claus Bornaes
IPC分类号: C07K14/775
CPC分类号: C12N9/6437 , A61K38/4846 , C12N9/647 , C12Y304/21021
摘要: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
摘要翻译: 人因子VII或人因子VIIa的Gla结构域变体,其相对于人因子VII或人因子VIIa包含1-15个氨基酸修饰,其中通过在位置34取代引入疏水性氨基酸残基; 或在36位具有氨基酸取代; 并使用变体治疗脑内出血(ICH)或创伤。
-
公开(公告)号:US20060252128A1
公开(公告)日:2006-11-09
申请号:US11379664
申请日:2006-04-21
申请人: Jesper Haaning , Kim Andersen , Claus Bornaes
发明人: Jesper Haaning , Kim Andersen , Claus Bornaes
CPC分类号: C12N9/6437 , A61K38/4846 , C12N9/647 , C12Y304/21021
摘要: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
摘要翻译: 人因子VII或人因子VIIa的Gla结构域变体,其相对于人因子VII或人因子VIIa包含1-15个氨基酸修饰,其中通过在位置34取代引入疏水性氨基酸残基; 或在36位具有氨基酸取代; 并使用变体治疗脑内出血(ICH)或创伤。
-
公开(公告)号:US20060241041A1
公开(公告)日:2006-10-26
申请号:US11424035
申请日:2006-06-14
申请人: Jesper Haaning , Kim Andersen , Claus Bornaes
发明人: Jesper Haaning , Kim Andersen , Claus Bornaes
CPC分类号: C12N9/6437 , A61K38/4846 , C12N9/647 , C12Y304/21021
摘要: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
摘要翻译: 人因子VII或人因子VIIa的Gla结构域变体,其相对于人因子VII或人因子VIIa包含1-15个氨基酸修饰,其中通过在位置34取代引入疏水性氨基酸残基; 或在36位具有氨基酸取代; 并使用变体治疗脑内出血(ICH)或创伤。
-
公开(公告)号:US20060270001A1
公开(公告)日:2006-11-30
申请号:US11381713
申请日:2006-05-04
申请人: Jesper Haaning , Kim Andersen
发明人: Jesper Haaning , Kim Andersen
IPC分类号: A61K38/37 , C07K14/745 , C07H21/04 , C12P21/04
CPC分类号: C12N9/6437 , A61K38/00 , C12Y304/21021
摘要: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.
-
公开(公告)号:US20070054366A1
公开(公告)日:2007-03-08
申请号:US10549506
申请日:2004-03-22
申请人: Kim Andersen , Mads Ropke , Jesper Haaning , Steven Glazer
发明人: Kim Andersen , Mads Ropke , Jesper Haaning , Steven Glazer
IPC分类号: C07K14/745 , C12P21/04 , C07H21/04
CPC分类号: C12N9/6437 , A61K38/4846 , C12Y304/21021
摘要: Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237 or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa.
摘要翻译: FVII或FVIIa的变体包含相对于hFVII或hFVIIa的196,237或341位的至少一个氨基酸修饰。 与rhFVIIa相比,变体表现出增加的凝血活性,即减少凝血时间。
-
公开(公告)号:US20060166874A1
公开(公告)日:2006-07-27
申请号:US10529624
申请日:2003-09-26
申请人: Jesper Haaning , Kim Andersen
发明人: Jesper Haaning , Kim Andersen
IPC分类号: A61K38/37 , C07H21/04 , C12P21/04 , C07K14/755
CPC分类号: A61K38/4846 , C07K14/755 , C12N9/6437 , C12Y304/21021
摘要: The present invention relates to novel Factor VII or VIIa variants comprising a substitution in at least one position selected from the group consisting of L39, 142, S43, K62, L65, F71, E82 and F275. Such variants exhibit increased clotting activity as compared to human wild-type Factor VIIa. The present invention also relates to use of such Factor VII or VIIa variants in therapy, in particular for the treatment of a variety of coagulation-related disorders.
摘要翻译: 本发明涉及包含在选自L39,142,S43,K62,L65,F71,E82和F275中的至少一个位置取代的新的因子VII或VIIa变体。 与人野生型因子VIIa相比,这些变体表现出增加的凝血活性。 本发明还涉及这种因子VII或VIIa变体在治疗中的用途,特别是用于治疗各种凝血相关疾病。
-
公开(公告)号:US20060111282A1
公开(公告)日:2006-05-25
申请号:US10512754
申请日:2003-04-29
申请人: Jesper Haaning , Kim Andersen
发明人: Jesper Haaning , Kim Andersen
IPC分类号: A61K38/37
CPC分类号: C12N9/6437 , A61K38/00 , C12Y304/21021
摘要: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.
摘要翻译: 本发明涉及因子VII(FVII)或因子VIIa(FVIIa)多肽的新型多肽变体,其中所述变体包含位置10和32的氨基酸取代,并且其中所述变体还包含共价连接到引入 位于Gla结构域之外的体内N-糖基化位点。 这样的多肽变体可用于治疗,特别是用于治疗各种凝血相关疾病如创伤。
-
公开(公告)号:US20060276377A1
公开(公告)日:2006-12-07
申请号:US11381718
申请日:2006-05-04
申请人: Jesper Haaning , Kim Andersen
发明人: Jesper Haaning , Kim Andersen
IPC分类号: A61K38/37 , C07K14/745 , A61K38/16 , C07H21/04 , C12P21/04
CPC分类号: C12N9/6437 , A61K38/00 , C12Y304/21021
摘要: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.
摘要翻译: 本发明涉及因子VII(FVII)或因子VIIa(FVIIa)多肽的新型多肽变体,其中所述变体包含位置10和32的氨基酸取代,并且其中所述变体还包含共价连接到引入 位于Gla结构域之外的体内N-糖基化位点。 这样的多肽变体可用于治疗,特别是用于治疗各种凝血相关疾病如创伤。
-
-
-
-
-
-
-
-
-